Cannabinoids for Pain Management and Neuroprotection From Concussion
Key facts
- Who runs it
- University of Regina
- Where
- Canada2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 34 people enrolled
- Started
- 15 Feb 2024
- Ended
- 30 Nov 2024
- Type of study
- Interventional
- Treatments tested
- Cannabis/Hemp Isolate Extract
- Record updated
- 6 May 2026
Who can take part
- Age
- 18 years to 35 years
- Sex
- Men only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Healthy male adults between 18-35 years of age that compete in contact sport athletics
- No known cerebrovascular or cardiovascular complications
- Not habitual recreational users of cannabis (i.e., <1 day/week) or tobacco users
- Agree not to consume any other cannabis or tobacco products while enrolled in the study
- Agree to list any prescription medications being taken
- Ability to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, perceptual-cognitive, and functional motor skills laboratory tests
Who cannot take part
- Use of cannabis-based therapy within 2 months (participants who have previously used a cannabis based therapy may be included if they have a 2 month period without use of cannabis based therapy prior to enrolment in the study)
- Initiation or dosage change of oral or injected steroids within past 3 months
- Medically supervised for anxiety, depression, or other neurological conditions
- Allergy or known intolerance to any of the compounds within the study preparation
- Inability to attend assessments on a regular basis at the pre-determined times, or failure to take drug on a daily basis
- Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator)
- Female
- Requirement to travel to the USA during study period; USA laws do not permit cross border with cannabis products
- Any level of cannabis in blood samples when sampled at the commencement of the study
- Concussion
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this open-label, placebo-controlled, dosage escalation study is to learn about the safety of a Cannabis/Hemp Isolate Extract in normal healthy adults engaged in elite contact sport competition.
Read full original descriptionShow less
The main question it aims to answer is:
• Are cannabis/hemp-based products with high CBD safe, well-tolerated and without adverse physiological and psychological dysfunction, when administered on a daily basis?
Participants will:
* be given CBD and a placebo. The placebo will be taken for 2 weeks prior to starting the CBD. Participants will start on a low dose of CBD, beginning at 5 mg CBD/kg body mass, which will be increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken; * have blood samples taken to analyse how much CBD is used in the body and for how long it lasts in the body (pharmacokinetics and pharmacodynamics); * have saliva samples collected for genetic analysis; * undergo testing sessions, which will include psychological and health questionnaires, equipment to record signals from the brain and heart, and safety laboratory tests.
The group in the trial
- Dose EscalationTreatment being tested
When participants start the CBD, they will be started on a low dose of CBD, beginning at 5 mg CBD/kg body mass, and then increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken.
Treatment: Cannabis/Hemp Isolate Extract
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Naturally Produced Cannabinoids for Pain Management and Neuroprotection From Concussion During Participation in Contact Sports: Dose Escalation
- Publications
- Record updated
- 6 May 2026